Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic is wireless in Europe

This article was originally published in The Gray Sheet

Executive Summary

Medtronic launches its Carelink Network with Conexus wireless telemetry system in Europe Aug. 30 after gaining a CE mark earlier in the month. The system, compatible with the firm's Concerto and Virtuoso cardiac rhythm management devices, allows data to be transmitted automatically from the implant to physicians when a change in the patient's condition arises, even if the patient is sleeping. Previously, patients in Europe with the Concerto or Virtuoso devices had to plug into a phone line to transmit data. The automatic wireless feature has been available to U.S. patients since 2006 (1"The Gray Sheet" May 22, 2006, p. 12)...

You may also be interested in...

Heart Rhythm Society Annual Meeting In Brief

ICD replacement woes?: Mayo Clinic physicians identified nine complications that resulted from 732 implantable cardioverter defibrillator replacement procedures performed at the clinic from 2000 through 2005 in research reported at the Heart Rhythm Society annual meeting May 18 in Boston. The group found that 162 of the replacements were due to recalls and advisories; 570 were elective procedures performed due to expected battery depletions. However, research recently published in the Journal of the American Medical Association and presented at the HRS meeting reported a notably higher complication rate. That study found 43 complications, including 31 requiring re-operation, resulting from 533 ICD replacement procedures performed in 17 Canadian centers between October 2004 and October 2005 (1"The Gray Sheet" May 1, 2006, p. 4). University of Western Ontario Professor Paul Gould, lead author of the latter study, said the observed complication rate "was much higher than we anticipated" and should make physicians think twice before replacing an ICD. Meanwhile, data from a 96-patient survey presented at the meeting by Mount Sinai Medical Center physicians revealed no significant difference in emotional status and overall quality of life between patients with recalled heart devices and devices that had not been recalled...

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts